ORLANDO, Fla. – Pfizer CEO Albert Bourla told CNBC Thursday people will most “likely” need another dose of the COVID-19 vaccine within a year of their full vaccination.
The pharmaceutical company, as well as Moderna, have been studying the possibility of requiring a third dose since earlier this year.
The ongoing studies are also looking at how effective a booster will be on immunity against COVID-19 caused by current and possibly new variants.
A study launched in February is using participants from the first Pfizer Phase 1 U.S. study who will be offered a third shot of the current vaccine 6 to 12 months after receiving their second shot regimen.